Pharmacokinetics and pharmacodynamics of IV induction agents short note In 5 pages

Reading File

Finding Sources

Searching PubMed

intravenous anesthetics AND pharmacokinetics

Searching the Web

intravenous induction agents pharmacokinetics pharmacodynamics propofol etomidate ketamine thiopental authoritative review

Finding Sources

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC6267518

Reading File

Finding Sources

Pharmacokinetics and Pharmacodynamics of IV Induction Agents

Introduction

Intravenous (IV) induction agents are drugs used to produce rapid unconsciousness at the start of general anesthesia. The commonly used agents are:

Propofol
Thiopental sodium
Etomidate
Ketamine
Midazolam

An ideal IV induction agent should have rapid onset and recovery, minimal cardiovascular and respiratory depression, analgesic effect, absence of adverse effects, and predictable elimination. No single agent fulfills all these requirements. The choice depends on patient condition, type of surgery, cardiovascular status, airway, and associated comorbidities.

Pharmacokinetics (PK) describes what the body does to the drug: distribution, metabolism, and elimination.
Pharmacodynamics (PD) describes what the drug does to the body: receptor action, clinical effects, and adverse effects.

General pharmacokinetic principles of IV induction agents

Most IV anesthetics are highly lipid soluble. After a rapid IV bolus, they reach the brain quickly because the brain receives high cardiac output. Thus, loss of consciousness occurs in one arm-brain circulation time, usually within 30 to 60 seconds.

Redistribution

With a single bolus, recovery of consciousness usually occurs by redistribution, not by metabolism. Drug concentration falls rapidly in the vessel-rich group, especially the brain, as the drug distributes into muscle and fat.

This is especially important for thiopental, propofol, etomidate, and ketamine. For example, ultra-short acting barbiturates such as thiopental produce short initial anesthesia mainly because they redistribute away from the brain; hepatic metabolism is responsible for final elimination. Miller's Anesthesia, 10e, Intravenous Anesthetics section.

Factors affecting induction and recovery

Cardiac output: Low cardiac output may increase time to peak brain concentration but can increase effective drug concentration and hemodynamic sensitivity.
Age: Elderly patients generally need lower doses because of reduced central volume of distribution, reduced clearance, and increased brain sensitivity.
Hypovolemia or shock: Dose requirement is lower, especially for propofol and thiopental.
Protein binding: Hypoalbuminemia increases free drug fraction for highly protein-bound drugs.
Hepatic and renal dysfunction: May prolong elimination of some agents or metabolites, particularly benzodiazepines.
Repeated boluses or infusion: Redistribution becomes less important and drug accumulation can delay recovery. Context-sensitive half-time is then more clinically relevant than elimination half-life.

1. Propofol

Dose and onset

Induction dose: 1.5 to 2.5 mg/kg IV in healthy adults
Lower dose: approximately 1 to 1.5 mg/kg in elderly, hypovolemic, or critically ill patients
Onset: 20 to 40 seconds
Duration after a single bolus: 5 to 10 minutes

Pharmacodynamics

Mechanism of action

Propofol enhances inhibitory neurotransmission by acting at the GABA-A receptor. It increases the effect of GABA at chloride channels, causing neuronal hyperpolarization and CNS depression. It is a hypnotic agent but provides no analgesia.

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 337.

CNS effects

Produces smooth, rapid induction and recovery.
Reduces cerebral metabolic rate for oxygen consumption (CMRO₂).
Reduces cerebral blood flow and intracranial pressure.
May reduce cerebral perfusion pressure if marked hypotension occurs.
Has anticonvulsant activity.
Produces less postoperative nausea and vomiting than many other induction agents.

Cardiovascular effects

Propofol commonly causes:

Hypotension due to arterial and venous vasodilation
Reduced systemic vascular resistance
Reduced venous return and cardiac output
Bradycardia due to reduced sympathetic tone and impaired baroreceptor reflexes

It must be used cautiously in hypovolemia, shock, severe cardiac disease, and elderly patients.

Respiratory effects

Dose-dependent respiratory depression
Apnea may occur after induction bolus
Decreases upper airway reflexes more than thiopental
Facilitates insertion of a laryngeal mask airway and tracheal intubation, sometimes even without neuromuscular blockade
May cause bronchodilation and has relatively low incidence of wheezing

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 340.

Other effects and adverse effects

Pain on injection, especially in small hand veins
Myoclonus is uncommon
Antiemetic effect
Hypertriglyceridemia with prolonged infusion due to lipid emulsion
Propofol infusion syndrome is rare but serious, characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure, and renal failure, particularly with high-dose prolonged infusion
Strict aseptic handling is needed because the lipid emulsion can support microbial growth

Pharmacokinetics

Highly lipid soluble and extensively protein bound.
Rapidly crosses the blood-brain barrier.
Rapid onset and rapid awakening after a bolus are due to redistribution.
Initial distribution half-life is approximately 2 to 8 minutes.
Metabolized mainly in the liver by conjugation to inactive metabolites.
Clearance exceeds hepatic blood flow, indicating important extrahepatic metabolism.
Inactive metabolites are excreted in urine.
High clearance and relatively short context-sensitive half-time make propofol suitable for total intravenous anesthesia and ambulatory surgery.

Morgan and Mikhail's Clinical Anesthesiology, 7e, pp. 338-339. A clinical PK/PD review of propofol also describes its high protein and erythrocyte binding, rapid brain entry, and cardiopulmonary dose-limiting effects.

Clinical uses

Routine induction of anesthesia
Total intravenous anesthesia
Sedation for endoscopy and short procedures
Day-care surgery
Neuroanesthesia, especially when rapid recovery and reduced intracranial pressure are desired

2. Thiopental Sodium

Thiopental is an ultra-short acting barbiturate. It was formerly the standard IV induction agent but has largely been replaced by propofol.

Dose and onset

Induction dose: 3 to 5 mg/kg IV
Onset: 20 to 30 seconds
Duration after single dose: 5 to 10 minutes

Pharmacodynamics

Mechanism of action

Thiopental acts mainly at the GABA-A receptor. It enhances GABA-mediated chloride conductance, producing CNS depression. At high concentrations, barbiturates may directly activate GABA-A channels.

It provides:

Hypnosis
Sedation
Amnesia
Anticonvulsant effect

It does not provide analgesia.

CNS effects

Reduces CMRO₂, cerebral blood flow, cerebral blood volume, and intracranial pressure.
Provides cerebral protection during focal cerebral ischemia.
Useful in patients with raised intracranial pressure if hemodynamics are maintained.
Can suppress seizures, but may also precipitate acute intermittent porphyria.

Cardiovascular effects

Thiopental causes:

Decreased mean arterial pressure
Decreased cardiac output
Venodilation with peripheral pooling of blood
Reduced venous return
Reflex tachycardia

Hypotension is more severe in hypovolemia, shock, elderly patients, and patients with poor cardiac reserve. The main mechanism is reduced venous tone and venous return. Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e, Cardiovascular Effects section.

Respiratory effects

Respiratory depression and apnea after rapid injection
Reduced ventilatory response to carbon dioxide
Depression of airway reflexes, though less than propofol
Histamine release may cause bronchospasm in susceptible patients

Pharmacokinetics

Highly lipid soluble and rapidly enters the brain.
Very high protein binding, approximately 75% to 85%, mainly to albumin.
Rapid onset occurs because of fast brain uptake.
Short duration after a single dose is due to redistribution from brain to muscle and fat.
Hepatic metabolism is the sole important route of elimination.
Elimination half-life is long, approximately 6 to 12 hours.
Repeated doses or infusion cause accumulation in adipose tissue and delayed recovery.

Miller's Anesthesia, 10e, Intravenous Anesthetics section.

Clinical uses

Induction of anesthesia where propofol is unsuitable
Control of refractory seizures or status epilepticus
Reduction of intracranial pressure
Cerebral protection in selected settings

Contraindications

Hypovolemia and shock
Severe cardiovascular instability
Acute intermittent porphyria
Severe asthma or airway obstruction, where respiratory depression and airway compromise are concerning

3. Etomidate

Etomidate is an imidazole derivative characterized by hemodynamic stability. It is particularly useful for induction in patients with severe cardiovascular disease or hemodynamic instability.

Dose and onset

Induction dose: 0.2 to 0.3 mg/kg IV
Onset: 30 to 60 seconds
Duration: 3 to 5 minutes

Pharmacodynamics

Mechanism of action

Etomidate acts on the GABA-A receptor, enhancing inhibitory neurotransmission. It depresses the reticular activating system, causing hypnosis and unconsciousness.

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 335.

It has:

Potent hypnotic action
No analgesic action
Minimal cardiovascular depression

CNS effects

Decreases CMRO₂, cerebral blood flow, and intracranial pressure.
Maintains cerebral perfusion better than propofol or thiopental in hemodynamically unstable patients.
May cause myoclonic movements during induction.
Does not provide analgesia.
Postoperative nausea and vomiting are relatively common.

Cardiovascular effects

Etomidate produces minimal change in:

Heart rate
Blood pressure
Cardiac output
Systemic vascular resistance

Therefore, it is valuable in patients with:

Hypovolemia
Ischemic heart disease
Valvular heart disease
Poor ventricular function
Shock states

However, laryngoscopy may produce tachycardia and hypertension if etomidate is used alone because anesthetic depth and sympathetic suppression may be inadequate.

Respiratory effects

Less respiratory depression than propofol or thiopental
Apnea can still occur after rapid IV injection
No significant histamine release

Endocrine effect

The major adverse effect is inhibition of adrenal steroid synthesis. Etomidate inhibits 11-beta-hydroxylase and, to a lesser degree, 17-alpha-hydroxylase. This reduces cortisol and aldosterone synthesis.

Thus:

A single induction dose can transiently suppress adrenal steroid production.
Continuous infusion for ICU sedation is avoided.
It should be used cautiously in septic or critically ill patients where adrenal suppression is undesirable.

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 336. A review of etomidate pharmacology confirms its minimal cardiorespiratory depression but emphasizes adrenal-axis suppression and unsuitability for prolonged infusion.

Pharmacokinetics

Rapid brain uptake because it is lipid soluble at physiologic pH.
Short duration after a bolus is mainly due to redistribution.
Metabolized by hepatic and plasma esterases to inactive metabolites.
Metabolites are excreted mainly through urine, with a smaller biliary component.
Terminal elimination half-life is approximately 3 to 5 hours.
Elderly and hypoalbuminemic patients require lower doses because clearance and protein binding may be reduced.
Renal impairment has relatively little effect on its overall pharmacokinetic profile.

Adverse effects

Pain on injection
Myoclonus, occurring commonly during induction
Postoperative nausea and vomiting
Adrenocortical suppression
Thrombophlebitis with propylene glycol formulation

4. Ketamine

Ketamine is a phencyclidine derivative that produces dissociative anesthesia. It is unique among IV induction agents because it produces hypnosis, amnesia, and strong analgesia while usually preserving spontaneous respiration and airway reflexes.

Dose and onset

IV induction dose: 1 to 2 mg/kg
Onset: 30 to 60 seconds
Duration: 10 to 15 minutes
IM induction dose: 4 to 10 mg/kg

Pharmacodynamics

Mechanism of action

Ketamine is primarily a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. It functionally dissociates the thalamocortical and limbic systems, so sensory input is not consciously processed.

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 330.

CNS effects

Produces dissociative anesthesia
Provides profound analgesia
Produces amnesia and unconsciousness
May cause nystagmus, open eyes, increased muscle tone, and purposeless movements despite adequate anesthesia
Emergence delirium, vivid dreams, and hallucinations may occur, especially in adults
Benzodiazepine premedication or coadministration with propofol can reduce emergence reactions

Older teaching suggested ketamine raises intracranial pressure. Current evidence indicates that under controlled ventilation and with coadministration of a GABAergic anesthetic, ketamine is not necessarily associated with raised ICP in neurologically injured patients. Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 334.

Cardiovascular effects

Ketamine usually increases:

Heart rate
Blood pressure
Cardiac output
Myocardial oxygen consumption

These effects result from sympathetic stimulation and increased circulating catecholamines. This is beneficial in trauma, hypovolemia, or hypotension.

However, in patients with depleted catecholamine stores, the direct myocardial depressant effect of ketamine may become apparent, causing hypotension.

Respiratory effects

Minimal respiratory depression at induction doses
Airway reflexes are relatively preserved
Potent bronchodilator, especially racemic ketamine
Useful in bronchospasm and asthma
Increased salivation and secretions may occur
Apnea can occur when ketamine is combined with opioids or other sedative agents

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 333.

Pharmacokinetics

Highly lipid soluble, with rapid CNS penetration.
Distribution half-life: approximately 2 to 4 minutes.
Rapid awakening after a single dose results from redistribution.
Extensive hepatic metabolism, mainly by CYP enzymes, to norketamine, an active metabolite.
High hepatic extraction ratio, approximately 0.9.
Elimination half-life: approximately 2 hours.
Metabolites are excreted mainly in urine.
Repeated doses can lead to tolerance and prolonged recovery.

Morgan and Mikhail's Clinical Anesthesiology, 7e, p. 332.

Clinical uses

Induction in hypovolemia, trauma, or shock
Bronchial asthma and bronchospasm
Painful procedures and emergency anesthesia
Pediatric anesthesia, especially where IV access is difficult
Procedural sedation
Analgesic adjunct in subanesthetic doses

5. Midazolam

Midazolam is a short-acting benzodiazepine. It is mainly used for anxiolysis, amnesia, sedation, and as an adjunct to induction rather than as the sole routine induction agent.

Dose and onset

Induction dose: 0.1 to 0.3 mg/kg IV
Smaller titrated doses are used for sedation
Onset: 1 to 3 minutes
Recovery is slower than with propofol

Pharmacodynamics

Mechanism of action

Midazolam acts at the benzodiazepine binding site on the GABA-A receptor. It increases the frequency of chloride channel opening in the presence of GABA, causing neuronal inhibition.

Effects

Anxiolysis
Sedation
Anterograde amnesia
Anticonvulsant activity
Muscle relaxation

It has no analgesic effect.

Cardiovascular and respiratory effects

Usually mild cardiovascular depression when used alone.
Can cause marked hypotension when combined with opioids.
Produces dose-dependent respiratory depression and apnea, especially with opioids, propofol, or in elderly patients.
Benzodiazepine-opioid interaction is synergistic.

Morgan and Mikhail's Clinical Anesthesiology, 7e, pp. 328-329.

Pharmacokinetics

Water soluble in acidic preparation but becomes lipid soluble at physiologic pH, allowing rapid CNS entry.
Metabolized in the liver by CYP3A4 to hydroxylated metabolites.
Active metabolite, alpha-hydroxymidazolam, is excreted renally.
Elimination half-life is about 1.5 to 3 hours, but may be prolonged in elderly patients, liver disease, renal impairment, obesity, and prolonged infusion.
Flumazenil can antagonize its sedative effects.

Clinical uses

Premedication
Sedation during regional anesthesia and procedures
Treatment of seizures
Induction when hemodynamic stability and amnesia are required, often with an opioid
Reduction of ketamine emergence phenomena

Comparative summary

Agent	Main receptor action	Analgesia	CV effect	Respiratory depression	Important adverse effect	Best clinical situation
Propofol	GABA-A facilitation	No	Marked hypotension possible	Marked, apnea common	Hypotension, pain on injection	Routine induction, day-care surgery, TIVA
Thiopental	GABA-A facilitation	No	Hypotension, tachycardia	Significant	Accumulation, porphyria risk	Raised ICP, seizure control
Etomidate	GABA-A facilitation	No	Minimal depression	Minimal to moderate	Myoclonus, adrenal suppression	Hemodynamic instability, cardiac disease
Ketamine	NMDA antagonism	Yes	Usually raises BP and HR	Minimal when used alone	Emergence delirium, secretions	Trauma, shock, asthma, painful procedures
Midazolam	GABA-A benzodiazepine site	No	Mild alone, marked with opioids	Significant with opioids	Delayed recovery, apnea	Premedication and sedation

Conclusion

IV induction agents produce rapid anesthesia because of high lipid solubility and rapid brain uptake. Recovery after a single bolus is usually due to redistribution from brain to peripheral tissues. Propofol is the most commonly used induction agent because of rapid, smooth recovery and antiemetic properties. Etomidate is useful when cardiovascular stability is required. Ketamine is particularly useful in trauma, hypotension, bronchospasm, and painful procedures because it provides analgesia and sympathetic stimulation. Thiopental remains useful for selected neuroanesthetic and anticonvulsant indications. Midazolam is primarily an adjunct for sedation, amnesia, and anxiolysis.

The induction agent should always be individualized according to the patient's cardiovascular state, airway, neurological condition, aspiration risk, and the planned anesthetic technique.

This is a shared conversation. Sign in to Orris to start your own chat.